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Abstract
Background—Acquired resistance to second-line drugs (SLD) is a problem in treating patients 
with drug-resistant tuberculosis (TB) worldwide. The objectives of this study were to identify risk 
factors for acquired resistance (AR) to injectable SLD and fluoroquinolones in the US National 
TB Surveillance System, 1993–2008.
Methods—We selected cases with initial and final drug susceptibility test (DST) results reported. 
We defined AR as resistance at the final DST but susceptibility to the same drug at the initial 
DST. We analyzed AR using 2-way frequency tables and multivariable logistic regression.
Results—Baseline prevalence of multidrug-resistant (MDR) and extensively drug-resistant 
(XDR)TB was 12.6% (1864/14,770) and 0.38% (56/14,770), respectively. Of 2,274 individuals 
without initial resistance to injectable SLD, 49 (2.2%) acquired resistance. Of 1,141 initially 
susceptible to fluoroquinolones, 32 (2.8%) acquired resistance. AR to injectable SLD was 
associated with age group 25–44 years (adjusted Odds Ratio [aOR], 2.7; 95% confidence interval 
[CI], 1.2–6.3), positive HIV status (aOR, 2.5; 95% CI, 1.3–4.7), MDR at treatment initiation 
(aOR, 5.5; 95% CI, 2.9–10.5), and treatment with any SLD (aOR, 2.4; 95% CI,1.2–4.7). AR to 
fluoroquinolones was associated with MDR TB at treatment initiation (aOR, 6.5; 95% CI, 2.9–
14.6).
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Conclusion—Among patients with initial and final DST reported, risk factors for AR to 
injectable SLD included age, positive HIV status, MDR TB and initial treatment with any SLD, 
while the only predictor for AR to fluoroquinolones was MDR TB at treatment initiation. 
Providers should consider monitoring SLD DST for MDR TB patients in the indicated subgroups.
INTRODUCTION
Antituberculosis drug resistance is a major public health problem around the world. The 
World Health Organization (WHO) estimates the global burden of multidrug-resistant 
(MDR) tuberculosis (TB), defined as TB resistant to at least isoniazid and rifampicin, as 
approximately 650,000 cases in 2011 (1).
Primary resistance occurs when a person is infected with a strain of M. tuberculosis that is 
already resistant to antituberculosis drug(s). Acquired drug resistance (AR) occurs when a 
person is infected with a drug-susceptible strain of M. tuberculosis that becomes drug-
resistant during treatment. AR occurs due to improper use of antibiotics such as inadequate 
treatment regimens or incomplete treatment (2–4). Acquisition of resistance to second-line 
drugs (SLDs) during MDR TB treatment (18–24 months) increases the risk of treatment 
failure (5–6) and the emergence of extensively drug-resistant TB (XDR TB) (7). XDR TB is 
a subset of MDR TB with further resistance to at least one of three injectable second-line 
drugs (SLDs) (amikacin, kanamycin, or capreomycin) and any fluoroquinolone (8). The 
latest WHO report of anti-tuberculosis drug resistance in the world estimated that 9.4% of 
MDR TB isolates were XDR TB (9). As of January 2012, 77 countries had reported to 
WHO at least one case of XDR-TB (10). Treatment outcomes among XDR TB patients are 
poor and mortality rates are similar to the pre-antibiotic era. According to the results of a 
recent meta-analysis of 13 observational studies, treatment of XDR TB succeeded in only 
43.7 % of cases, and mortality was 20.8% (11).
In the United States, 63 cases of XDR TB based on initial DST results have been reported in 
1993–2011 (12, plus 6 cases in 2011 CDC unpublished). Little is known about the causes of 
acquired resistance to SLD during treatment, as most published reports to date have been 
descriptive (11–19). As acquired resistance to the second-line TB medications severely 
compromises treatment options for patients with MDR TB, understanding the factors that 
lead to acquired resistance to SLD may help identify patients at risk and measures for 
prevention (3).
To determine the frequency of and risk factors for acquired resistance to key second-line 
antituberculosis drugs, we analyzed data from the U.S. National TB Surveillance System 
(NTSS) for the years 1993–2008.
METHODS
We analyzed data from all culture-positive TB cases in CDC’s NTSS from all 50 states and 
the District of Columbia between January 1993 and December 2008 (20). The NTSS 
includes sociodemographic and clinical information, as well as initial and final drug 
susceptibility test (DST) results. While DST for first-line drugs on the initial positive culture 
is routine in the U.S., second-line DST and repeated DST are performed only when 
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indicated. Final DST data and treatment outcomes are reported within 12 to 24 months after 
the end of treatment. All injectable SLDs (amikacin, kanamycin, capreomycin) and FQs 
(ofloxacin, ciprofloxacin) considered in this analysis were available for treatment in the U.S. 
from 1993.
Case definitions
We included in the analysis culture-positive cases with both initial and final DST results 
reported for second-line anti-TB drugs, specifically amikacin, kanamycin, capreomycin 
(injectable second-line drugs, INJ SLD), ofloxacin and ciprofloxacin (fluoroquinolones, 
FQ). Initial DST is defined as the first available DST for a case; final DST is defined as the 
last available DST for the same drug. Acquired resistance was defined as drug resistance at 
the final DST but susceptibility to the same drug at the initial DST.
In this nested case-control analysis, we defined a case as an individual who acquired 
resistance to at least one INJ SLD or one FQ during treatment. A control was defined as an 
individual who did not acquire resistance. We excluded cases that had resistance at the 
initial DST to INJ SLD or FQ.
All variables were defined according to their standard usage in the NTSS which has been 
described in detail elsewhere (20).
Statistical analysis
We compared the distribution of demographic, social, and clinical characteristics among TB 
cases with versus without acquired SLD drug resistance, assessing differences in categorical 
variables with Pearson’s chi square test. Specific demographic and social characteristics 
examined were gender, age, race/ethnicity, country of origin, illicit drug use, excess alcohol 
consumption, history of homelessness, occupation and imprisonment at the time of 
diagnosis. Clinical characteristics included a prior history of TB, sputum-smear status at 
diagnosis, chest radiograph results (normal versus abnormal), radiographic abnormalities 
(cavitary versus non-cavitary disease), anatomic site of disease (i.e., pulmonary or not 
pulmonary), HIV status, MDR TB, and specific drug regimens at the start of treatment.
We stratified the analysis of risk factors versus acquired resistance by other covariates to 
assess potential confounding and effect modification. Multivariable logistic regression was 
used to assess the independent associations between selected characteristics and acquired 
resistance. Criteria for including variables in the initial multivariable logistic regression 
model included a p-value <0.10 in univariate analysis or biologically plausible association 
with outcome of interest. Odds ratios (OR) and 95% confidence intervals (95% CI) were 
used to measure the magnitude and precision of the association of each factor with the 
outcome of interest. We used two-sided tests of significance; P<0.05 was considered 
statistically significant.
These data were collected and analyzed as part of routine public health surveillance, not as 
human subject’s research requiring IRB approval.
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RESULTS
Among 222,897 culture-positive TB cases, reported in the United States from 1993 to 2008, 
31,733 (14.3%) had initial DST results to at least one SLD (Figure 1). Of these, 31,226 
(98.4%) cases had initial DST results to at least one injectable SLD and 15,337 (48.3%) to at 
least one FQ; 14,830 (6.7%) had initial DST results to both classes of SLD. Of these, 14,770 
cases also had initial DST results to isoniazid and rifampin. MDR TB was diagnosed in 
1,864 (12.6%) cases and 56 (0.38%) had XDR TB at treatment initiation (baseline XDR).
Among 31,226 cases with initial DST results to INJ SLD, 2,329 (7.5%) had final DST 
results to the same drug: 89% had both initial and final DST results for kanamycin, 16% for 
amikacin, and 70% for capreomycin. Of these, 43 cases had resistance to one INJ SLD at the 
initial DST but DST results for the other INJ SLDs were not reported; 12 cases were 
resistant to all INJ SLD at the initial DST. Therefore, 55 cases could not have acquired 
resistance and were excluded from the analysis (Figure 1). Kanamycin, amikacin and 
capreomycin were included in the initial treatment regimen for 13 (0.6%), 35 (1.5%) and 58 
(2.6%) cases, respectively. Of 2,274 analyzed cases, 49 (2.2%) acquired resistance to at least 
one INJ SLD. The annual number of acquired INJ SLD resistance cases decreased from a 
maximum of 10 in 1995 to zero in 2008, fluctuating around a mean of 2.2 per year during 
the past decade (Figure 2).
Among 15,337 culture-positive TB cases with initial DST results to at least one FQ, 1,187 
(7.7%) had final DST results to the same FQ. 39 culture-positive TB cases were resistant to 
one FQ on initial DST and did not have initial DST to other FQ; 17 cases were resistant to 
both FQs on initial DST, thus 56 cases could not have acquired resistance and were 
excluded from the analysis (Figure 1). Among 1,141 cases with both initial and final DST 
results to FQ, 32 (2.8%) acquired resistance to at least one FQ. The annual number of 
acquired FQ resistance cases decreased from a maximum of 4 in 1994 to 1 case in 2008, 
fluctuating around a mean 1.8 per year during the past decade (Figure 2).
Of 14,830 culture-positive cases with initial DST results to both INJ SLD and FQ, 1,155 
(7.8%) had final DSTs to the same drug. Seventy-two cases were excluded: 22 cases were 
initially resistant to all reported INJ SLD and FQ; 50 cases were initially resistant to one INJ 
SLD and one FQ but DST results for the other INJ SLDs and FQs were not reported. Of the 
remaining 1,083 cases, 5 (0.5%) acquired resistance to both INJ SLD and FQ. All five had 
MDR TB at the initial DST, thus they became XDR TB. All five cases were HIV positive 
and occurred before 2001. Twenty-four (2.2%) of 1,083 individuals acquired resistance to 
INJ SLD only, and coincidentally 24 cases (2.2%) of 1, 083 acquired resistance to FQ only.
Risk factors for acquired resistance to injectable second-line drugs
Of the 49 cases with acquired resistance to INJ SLD, the majority (36/49, 73.5%) were aged 
25 to 44 years, 27 (55.1%) were male, 21 (42.9%) were Hispanic, 27 (55.1%) were US-born, 
and 22 (44.9%) were unemployed (Table 1). Twenty-two (45%) of these 49 cases were 
HIV-infected, 34 (69.4%) had MDR TB at the beginning of treatment, and 19 (38.8%) had 
an initial treatment regimen that included at least one SLD (Table 2). Most cases with 
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acquired resistance to INJ SLD had pulmonary disease (36, 73.5%). Among 40 individuals 
with abnormal chest radiographs, the majority had non-cavitary abnormalities (24, 60%).
In univariate analysis significant predictors of acquired resistance to INJ SLD included 
female gender (Odds Ratio [OR], 2.1; 95% CI, 1.2–3.6), age group 25 to 44 years (OR, 3.7; 
95% CI, 1.7–8.4, versus the reference age-group 45–64), Hispanic ethnicity (OR, 4.0; 95% 
CI, 1.6–9.9, compared to non-Hispanic whites), positive HIV status (OR, 4.9; 95% CI, 2.8–
8.7), extra pulmonary disease (OR, 3.3; 95% CI, 1.4–8.1), normal chest X-ray result (OR, 
2.5; 95% CI, 1.1–6.0), MDR TB at initial DST (OR, 8.3; 95% CI, 4.5–15.3) and having at 
least one SLD in the initial treatment regimen (OR, 5.4; 95% CI,2.9–10.2) (Table 3). 
Stratified analysis did not reveal any potential effect modifiers among sociodemographic 
and clinical characteristics.
In multivariable logistic regression, significant predictors of acquired resistance to INJ SLD 
included: age group 25–44 years (aOR, 2.7; 95% CI, 1.2–6.3), positive HIV status (aOR, 
2.5; 95% CI, 1.3–4.7), MDR TB at initial DST (aOR, 5.5; 95% CI, 2.9–10.5), and initial 
treatment with any SLD (aOR, 2.4; 95% CI, 1.2–4.7).
Risk factors for acquired resistance to fluoroquinolones
Among 32 persons who acquired resistance to FQ, the majority were male (22/32, 68.8%), 
15 were aged 25 to 44 years (46.9%), 13 (40.6%) were Hispanic, 17 (53.1%) were US-born, 
19 (59.4%) were unemployed, 5 (15.6%) used illicit drugs and 2 (6.3%) were homeless 
(Table 1). Nine (28.1%) patients with acquired resistance to FQ were HIV-infected, 24 
(75.0%) had MDR TB at the beginning of TB treatment, and 10 (31.3%) had an initial 
treatment regimen that included at least one SLD (Table 2). The majority had pulmonary 
disease (25/32, 78.1%). Six (21.4%) were sputum-smear negative at the start of treatment 
and 4 (12.5%) had previous TB episodes.
In univariate analysis significant predictors of acquired resistance to FQ were MDR TB at 
initial DST (OR, 6.5; 95% CI, 2.9–14.3) and having at least one SLD included in the initial 
treatment regimen (OR, 2.3; 95% CI, 1.1–4.9) (Table 4). In multivariable analysis, MDR TB 
at initial DST (aOR, 6.5; 95% CI, 2.9–14.6) was the only statistically significant risk factor 
for acquired resistance to fluoroquinolones.
DISCUSSION
The present study provides the first comprehensive assessment of predictors of acquired 
resistance to two key classes of second-line antituberculosis drugs, fluoroquinolones and 
second-line injectable agents. From 1993 to 2008, among culture-positive TB cases with 
both initial and final DST results, 49 (2.2%) acquired resistance to INJ SLD and 32 (2.8%) 
acquired resistance to FQ. Five baseline MDR TB cases acquired resistance to both INJ SLD 
and FQ, and thus developed XDR TB. The number of cases with acquired drug resistance 
declined after 1993. The decrease in the frequency of AR beginning in 1993 may be 
attributed to the public health response to the TB epidemic, including greatly improved TB 
control activities and increased proportion of patients treated under directly observed 
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therapy (DOT) in the US from that time. However, acquisition of resistance to SLD in the 
U.S. continues to occur.
MDR TB was an independent predictor of acquired resistance to INJ SLD and FQ, and it 
was the only predictor for acquired resistance to FQ. Acquired resistance to INJ SLD was 
also independently associated with HIV status and having any SLD in the initial treatment 
regimen. Age group 25–44 years was the only demographic predictor for acquisition of 
resistance to INJ SLD, increasing the odds 2.7-fold. In this age group, cases who acquired 
resistance include a substantially higher proportion of HIV infected cases and illicit drug 
users compared with controls. No statistically significant association was identified between 
previous TB treatment and the acquisition of resistance to either group of SLD. The risk 
factors for acquired resistance to the injectable drugs and the FQs could be different because 
injectable second-line drugs have been available in the US since the 1950s, while FQs have 
been used for TB treatment only since the 1990s. Therefore the sample size for acquired 
resistance to FQs is smaller than for injectable second-line drugs, especially in the 25–44 
age group and among those who were HIV positive.
Several groups have reported the development of FQ-resistant TB and XDR TB during 
treatment (6–14), but not predictors for acquisition of resistance. There are very few 
publications on acquisition of second-line drug resistance, likely due to lack of capacity for 
the laboratory testing (21–22). Treatment with second-line drugs was associated with XDR 
TB in South Korea and also in Tugela Ferry, South Africa (21–22). Having MDR TB at the 
start of treatment appears to be the strongest consistent factor for acquired resistance to 
SLD.
Our study has several limitations. Drug susceptibility testing of M. tuberculosis to first-line 
drugs is performed and reported routinely in the United States, however testing of second-
line drugs and repeat testing is performed on an individual basis, according to the 
physician’s request. Most cases in NTSS had no reported DST results to SLDs and no repeat 
DST after the initial testing. Therefore, our results did not reflect SLD resistance among all 
reported TB cases, but only among those with reported results. In addition, among all cases 
with initial DST results reported, 10.3% (3,207/31,226) in the INJ SLD group and 9.9% 
(1,516/15,337) in the FQ group died; while about 3% (979/31,226 in the INJ SLD group and 
501/15,337 in the FQ group) were lost to follow up without final DST result. Thus, this 
study underestimates the real number of cases with acquired SLD resistance in the United 
States, but it is based on the most complete national data currently available. Also, as 
genotyping of both initial and final isolates was not available, we could not ensure that the 
same strain was tested. Therefore, we could not exclude infection with mixed strains, re-
infection, or laboratory errors. However, the risk of re-infection during TB treatment in the 
US is low (23–24). The U.S. National TB Genotyping Service database may help address 
these issues in the future (25). Finally, only the initial treatment regimen is reported in the 
NTSS, and important changes to TB therapy could be made during treatment. Accordingly 
we did not have detailed information about TB treatment for this analysis. The CDC has 
recently established an MDR/XDR TB registry collecting information on treatment 
regimens with the aim to further investigate this issue.
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In conclusion, our study demonstrated that in spite of declining trends in SLD resistance, the 
problem of acquired SLD resistance, while rare, still persists in the United States. The 
proportion of acquired resistance was larger among MDR TB patients, patients with positive 
HIV status, and those with SLD in the initial treatment regimen. Since emergence of 
resistance to second-line TB medication severely compromises the treatment regimen 
options for TB patients, identification of patients at risk and prevention of further resistance 
is important. Patients in these subgroups should be prioritized for fast-track DST and rapid 
molecular tests for drug resistance and strictly follow supervised treatment based on the drug 
susceptibility test results. Earlier identification of patients at risk for developing XDR TB 
enables more diligent infection control measures, critical for preventing transmission of the 
disease.
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Summary
This study provides the first comprehensive assessment of predictors of acquired 
resistance to two key classes of second-line antituberculosis drugs that may help identify 
patients at greater risk for developing XDR TB.
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Figure 1. Selection of Patient Population
Note: DST - Drug Susceptibility Testing
SLD - Second-Line Drugs
INJ SLD – Injectable Second-Line Drugs
FQ – Fluoroquinolones
AR – Acquired resistance
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Figure 2. Number and percent of acquired resistance cases in the US by year, 1993–2008
Note: INJ – Injectable Second-Line Drugs
FQ – Fluoroquinolones
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